Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors – AARD

Pomerantz LLP announced a securities class-action lawsuit against Aardvark Therapeutics and certain officers and directors, covering investors who acquired shares in or traceable to its February 13, 2025 IPO and those who bought securities through May 14, 2026. The suit, filed in the Southern District of California under docket 26-cv-04643, alleges violations of the Securities Act of 1933 and the Securities Exchange Act of 1934. The litigation presents a company-specific legal and governance overhang for AARD shares.

Analysis

This is primarily a liquidity and governance-overhang event rather than a fundamental read-through until the underlying allegations and claimed damages are independently assessed. For a recent IPO with a limited trading history, securities litigation can widen the perceived governance discount, raise future equity-financing costs, and reduce institutional willingness to support follow-on capital raises. The near-term pressure is likely amplified if ownership is concentrated, borrow is scarce, or lock-up-related supply remains available.

Over the next 1-3 months, the relevant catalyst is not the filing itself but whether a lead plaintiff is appointed, a consolidated complaint identifies verifiable disclosure failures, or the company revises operating, clinical, or commercial guidance. A dismissal motion, insurance coverage confirmation, or a clearly immaterial alleged-damages profile would reduce the overhang; conversely, regulatory inquiries, executive departures, delayed filings, or a dilutive financing would convert the legal headline into a more durable valuation problem.

Consensus often overweights the initial litigation headline: plaintiff-law-firm announcements frequently precede a long procedural period and do not establish liability. The more important 6-18 month question is whether the company has sufficient cash runway to avoid financing during legal uncertainty; absent that balance-sheet vulnerability or a connected operational disclosure issue, any indiscriminate selloff may be temporary rather than a standalone short thesis.

Key Decisions for Investors

• Do not initiate a directional position solely on this announcement; place AARD on a 30-60 day litigation watchlist and reassess after the first substantive complaint, lead-plaintiff ruling, or company response.
• For existing long exposure, reduce position size or hedge into liquidity windows if AARD breaks below its post-news support level on rising volume; treat a guidance cut, delayed periodic filing, or equity raise as thesis-invalidating events requiring a fuller exit.
• Consider a tactical short only if borrow is available at an acceptable carry cost and a separate fundamental catalyst emerges, such as cash-runway compression or revised clinical/commercial guidance. Size modestly because dismissal risk and low-float short-covering can create asymmetric upside; target a 1.5-2.0x reward-to-risk profile with a hard stop above the pre-filing trading range.
• Monitor cash balance, quarterly operating burn, ATM/shelf-registration activity, insider sales, and D&O insurance disclosures. A funded runway of at least 18 months with stable guidance would argue against maintaining a litigation-driven short.